EcoDrugPlus

Bcl2 Related Protein A1

Ensembl ID : ENSBTAG00000000735
Gene Symbol: BCL2A1
5 Cross references
137 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSBTAG00000020566
Gene Symbol: BCR
10 Enzyme and pathways 5 Cross references
298 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSBTAG00000019250
Gene Symbol: BTK
22 Enzyme and pathways 5 Cross references
219 Possible Orthologues:

C-C Chemokine Receptor Type 1-Like

Ensembl ID : ENSBTAG00000031355
Gene Symbol: LOC529196
4 Cross references
161 Possible Orthologues:

C-C Motif Chemokine Receptor 2

Ensembl ID : ENSBTAG00000013586
Gene Symbol: CCR2
13 Enzyme and pathways 5 Cross references
161 Possible Orthologues:

C-C Motif Chemokine Receptor 4

Ensembl ID : ENSBTAG00000034883
Gene Symbol: CCR4
8 Enzyme and pathways 5 Cross references
125 Possible Orthologues:

C-C Motif Chemokine Receptor 5

Ensembl ID : ENSBTAG00000008099
Gene Symbol: CCR5
8 Enzyme and pathways 4 Cross references
162 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSBTAG00000031348
Gene Symbol: CCR9
8 Enzyme and pathways 5 Cross references
277 Possible Orthologues:

C-X-C Motif Chemokine Ligand 8

Ensembl ID : ENSBTAG00000019716
Gene Symbol: CXCL8
8 Enzyme and pathways 5 Cross references
151 Possible Orthologues:

C-X-C Motif Chemokine Receptor 2

Ensembl ID : ENSBTAG00000038042
Gene Symbol: CXCR2
11 Enzyme and pathways 4 Cross references
264 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSBTAG00000001060
Gene Symbol: CXCR4
12 Enzyme and pathways 5 Cross references
230 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSBTAG00000006589
Gene Symbol: CFTR
17 Enzyme and pathways 5 Cross references
229 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).